Adrenocortical carcinoma · 6 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Mitotane and EDP Variant #01 | — | R 1 830 | 28d | — | 14.8 mo | — | — | 1 |
Doxorubicin monotherapy Variant #10 | — | R 1 293 | 21d | ~6.0 mo | ~8.2 mo | ~9 | ~R 11 639 PFS proxy · indirect | 18 |
Cisplatin and Mitotane Variant #01 Partial | — | R 500 | 21d | — | — | — | — | — |
Mitotane monotherapy N/A - secondary systemic drug | — | R 0 | 28d | — | — | — | — | — |
Mitotane and Streptozocin N/A - secondary systemic drug | — | R 0 | 21d | — | — | — | — | — |
Placebo Partial | — | — | — | — | — | — | — | 1 |
6 of 6 regimens shown